Identification of long non-coding RNA signature for paclitaxel-resistant patients with advanced ovarian cancer
Metrics: PDF 1192 views | HTML 2276 views | ?
Luqing Wang1,*, Yanjun Hu2,*, Xiaohong Xiang3, Kai Qu3 and Yue Teng4
1Department of Nuclear Medicine, Liaocheng People’s Hospital, Taishan Medical College, Liaocheng 252000, China
2Department of Clinical Laboratory, Liaocheng People’s Hospital, Taishan Medical College, Liaocheng 252000, China
3Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
4Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
*These authors have contributed equally to this work
Yue Teng, email: [email protected]
Kai Qu, email: [email protected]
Keywords: long non-coding RNA, epithelial ovarian cancer, paclitaxel, chemoresistance
Received: May 07, 2017 Accepted: June 19, 2017 Published: August 02, 2017
Ovarian cancer is the most lethal gynecologic malignancy, characterized by late diagnosis, frequent relapse, and easy development of chemoresistance. Recent studies suggest that lncRNAs are involved in ovarian cancer onset and progression, as well as the resistance in paclitaxel-containing chemotherapy. However, the genome-wide expression pattern and associated functional implications of lncRNAs in paclitaxel-resistant ovarian cancer cells remain undetermined. In the present study, we identified a panel of lncRNAs aberrantly expressed in both paclitaxel resistant ovarian cancer tissues and cell lines, including XR_948297, XR_947831, XR_938728, XR_938392, NR_103801, NR_073113, and NR_036503. Moreover, the seven-lncRNA signature showed a relatively high predictive accuracy of chemoresistance with an area under the ROC curve (AUC) of 0.93, and was associated with progression-free survival inovarian cancer patients (HR=2.05, p=0.015). Our function prediction demonstrated that the seven-lncRNA signature was positively correlated with a cluster containing 129 genes enriched in insulin secretion-related pathway. Our findings suggest that the seven-lncRNA signature may be utilized as potent biomarkers for predicting chemoresistance for ovarian cancer patients with paclitaxel-containing chemotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.